Orchestra BioMed Holdings, Inc. (OBIO) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in New Hope, PA, United States. The current CEO is David Hochman.
OBIO has IPO date of 2020-08-04, 70 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $263.93M.
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
